26 results about "Adiponectin" patented technology

The invention discloses a juvenile depressive disorder diagnosis marker, a depressive disorder diagnosis model and application thereof, and relates to the technical field of mental disorder diagnosis. Adiponectin is applied to auxiliary diagnosis or diagnosis of adolescent depressive disorder, the AUC value of a diagnosis model is larger than 0.7, and the adiponectin is high in diagnosis sensitivity and specificity and can serve as a diagnosis or auxiliary diagnosis marker of adolescent depressive disorder. Adiponectin and other indexes are combined for detection, the diagnosis performance of auxiliary diagnosis of juvenile depressive disorder can be improved, and the method has a good clinical application prospect.

This invention discloses a method and sensor for adiponectin detection using a polyaniline and polyacrylic acid-modified wire mesh carbon electrode, relating to the field of adiponectin detection technology. The method involves electrochemically activating the wire mesh carbon electrode, electropolymerizing it to form a polyaniline-polyacrylic acid composite modification layer, immobilizing adiponectin monoclonal antibody after activation with N-hydroxysuccinimide and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide, blocking the antibody with bovine serum albumin, and reacting it with a serum sample. The adiponectin concentration is determined based on the peak potential shift and peak current change. This invention simultaneously achieves both conductive transport and antibody immobilization, reduces non-specific adsorption and serum interference, and improves detection sensitivity, repeatability, and quantitative accuracy.

The invention belongs to the technical field of electrochemical analysis and detection, and particularly relates to an electrochemical immunosensor for detecting adiponectin as well as a preparation method and application of the electrochemical immunosensor. The preparation method comprises the following steps: (1) connecting a screen-printed electrode SPCE to an electrochemical workstation by using a 0.01 M PBS (Phosphate Buffer Solution) with the pH value of 7.4, performing-0.2 V-1. 2V cyclic voltammetry scanning, and activating for 10 circles under 50mV / S; and (2) by taking 0.01-1M H2SO4 as a base solution, connecting the screen-printed electrode SPCE to an electrochemical workstation, carrying out electro-polymerization on poly-o-phenylenediamine in a 50-100mM o-phenylenediamine and NH2-UiO-66 solution to form a poly-o-phenylenediamine and NH2-UiO-66 composite modified electrode, washing with deionized water, and drying at room temperature. (3) soaking the modified electrode in a glutaraldehyde solution for 10-70 minutes, cleaning with deionized water, drying at room temperature, adding 10-100 [mu] L of ADPN antibody solution and 100-600 [mu] g / mL of ADPN antibody solution, and incubating; and (4) washing with ionized water, drying at room temperature, preventing non-specific binding sites at 37 DEG C for 0.5-1.5 hours by using 3-10 microliters of 0.8-1.2 wt% casein solution, and washing the screen-printed electrode again to obtain the electrochemical immunosensor.

The application discloses a rice anti-Rhizoctonia solani leptin receptor OsPLS3 protein and an encoding protein and application thereof. The rice leptin receptor OsPLS3 protein has an amino acid sequence as shown in SEQ ID NO. 3. A coding gene of the rice leptin receptor gene OsPLS3 has a genomic nucleotide sequence as shown in SEQ ID NO. 1, and an open reading frame nucleotide sequence of the rice leptin receptor gene OsPLS3 is as shown in SEQ ID NO. 2. Experiments prove that overexpression of the rice leptin receptor gene OsPLS3 in the application in rice can improve the resistance of the rice to the Rhizoctonia solani, and the rice is more susceptible to the Rhizoctonia solani after knockout, namely, the OsPLS3 positively regulates the resistance of the rice to the Rhizoctonia solani. The rice leptin receptor gene OsPLS3 has important production value for breeding of the rice resistant to the Rhizoctonia solani.

The present application provides a method for producing a Citrus medica L. var. sarcodactylis fermentate with the effect of increasing polyphenol intake and adiponectin content. The method for producing a Citrus medica L. var. sarcodactylis fermentate with the effect of lowering blood lipids comprises the following steps: washing, air-drying, and breaking the cell wall, inoculating and fermenting, comprehensive filtering, sterilizing, and finally forming a Citrus medica L. var. sarcodactylis fermentate that can increase the total polyphenol content in the human body and improve the adiponectin content in the body.

The present application relates to the technical field of in vitro diagnosis, in particular to a chemiluminescence-based adiponectin detection method, which uses MQ silicon resin-coated Fe3O4 magnetic microspheres as a solid-phase carrier, captures adiponectin in a sample through a double-antibody sandwich immunoreaction, and uses HRP enzyme-labeled detection antibodies to combine with a luminol-phenolic enhanced chemiluminescence system for signal detection. The key lies in significantly reducing non-specific background by optimizing washing conditions and substrate formula, and regulating luminescence kinetics to adapt to the reading window of mainstream chemiluminescence instruments. The present application uses HRP enzyme-catalyzed cascade amplification and an optimized luminol enhancement system, and the detection lower limit is better than that of conventional methods, meeting the needs of early metabolic risk screening for ultra-low concentration detection, the linear detection range covers 0.01 mg / L to 100 mg / L, effectively avoiding the common hook effect in high-concentration samples, and the signal-to-noise ratio is greatly improved, ensuring the reliability of low-value sample detection.

A method for determining the amount of adiponectin in a sample by mass spectrometry includes: (a) subjecting adiponectin from the sample to an ionization source under conditions suitable for generating one or more adiponectin ions detectable by mass spectrometry; (b) determining the amount of one or more adiponectin ions by mass spectrometry; and (c) determining the amount of adiponectin in the sample from the amount of one or more adiponectin ions determined in step (b).

Compositions and methods use one or more feline circulating proteins as markers for early chronic kidney disease (CKD) to diagnose and / or treat CKD. A method of diagnosing chronic kidney disease (CKD) in a feline can include measuring an amount of each of at least one circulating protein from the feline. The at least one circulating protein is one or more of adiponectin (ADIPOQ), antibacterial peptide (CAMP), kinetin-like protein (KIF12), plasma retinol binding protein (RBP4), Ig-like domain containing protein (ZKSCAN1), blood coagulation factor X (F10), fibronectin (FN1), and mixtures thereof. The method further comprises comparing the amount of each of the at least one circulating protein from the feline to a respective predetermined value or a respective predetermined range. The method further comprises diagnosing the feline as having or not having early CKD based on the comparison.

The present application discloses the use of FGF21 / GLP-1 fusion proteins in the preparation of a medicament for preventing and / or treating at least one of type 2 diabetes, obesity, steatohepatitis, and triglyceridemia. The FGF21 / GLP-1 fusion proteins of the present application are effective in treating at least one of type 2 diabetes, obesity, steatohepatitis, and triglyceridemia, and in particular, can reduce at least one of HbA1c, blood glucose, body weight, liver fat content, ALT, AST, glutamyl transpeptidase, triglyceride, total cholesterol, low-density lipoprotein cholesterol, or increase at least one of adiponectin, insulin sensitivity, and beta-cell function in the subject.

The present invention relates to a novel peptide derivative, which is a partially modified adiponectin receptor peptide and has higher stability and superior p-AMPK activity than existing adiponectin receptor peptides, and has the advantage of being advantageous for drug formulation due to improved physical properties and activity. Therefore, the peptide derivative of the present invention can be used for preventing or treating skin inflammatory diseases, wounds, hair loss, fibrosis, metabolic diseases, or cancer, and for preventing or improving aging, sensitive skin, wrinkles, or moisture.

The application discloses a method for up-regulating adiponectin of perivascular adipose tissue, and belongs to the technical field of molecular biology. The method is targeted at cells of perivascular adipose tissue, increases mRNA and protein expression of LRP1 of adipocytes, activates an autophagy-related pathway, and reduces expression of proinflammatory factors.

The invention relates to the field of stem cell culture, in particular to adiponectin gene modified mesenchymal stem cells as well as a preparation method, a medicine and application thereof. The adiponectin gene modified mesenchymal stem cell provided by the invention can overexpress adiponectin to stimulate islet cells, regulate sugar stimulation response and improve insulin secretion amount. The preparation method of the adiponectin gene modified mesenchymal stem cell provided by the invention is simple, and the prepared adiponectin gene modified mesenchymal stem cell is higher in insulin secretion amount and longer in action time in an INS-1 cell sugar stimulation experiment.

The invention relates to an adiponectin receptor regulating peptide as well as a composition, a product and application thereof. The amino acid sequence of the adiponectin receptor regulating peptide is as follows: (a), any one of the amino acid sequences as shown in SEQ ID NO. 1 to 30, SEQ ID NO. 32, SEQ ID NO. 35 to 39, SEQ ID NO. 42, SEQ ID NO. 46, SEQ ID NO. 47, SEQ ID NO. 49 and SEQ ID NO. 50; or (b) any one of amino acid sequences which are obtained by modifying the N end and / or the C end of the adiponectin receptor regulating peptide limited by (a) and have the same or similar functions. The adiponectin receptor regulating peptide provided by the invention can activate an adiponectin receptor / AMPK signal channel and promote hair growth, has multiple effects of oxidation resistance, inflammation resistance and apoptosis resistance, can improve skin aging, and has wide application prospects in the fields of medicines, foods and cosmetics.

A herbal composition for the treatment of a variety of metabolic disorders in mammals, especially human beings, is disclosed. A method of preparing the herbal composition is also disclosed. The herbal composition treats and alleviates a plurality of metabolic disorders, including central obesity, high blood pressure levels, high blood sugar levels, stress-induced fatigue, and type 2 diabetes. The herbal composition comprises the extracts of Dolichos lablab, Achyranthes aspera, and at least one of Cinnamomum zeylanicum and Cinnamomum cassia. The aforementioned extracts are present in the herbal composition at a predetermined weight range. The aforementioned extracts are standardized to contain active compounds, including proanthocyanidins, saponins, polyphenols, and tannins, in a predetermined concentration and in predetermined purity levels. The herbal composition causes an enhancement of adiponectin levels and high-density lipoprotein (HDL) levels, and a reduction in the accumulation of adipose tissue, total cholesterol levels, triglyceride levels, and low-density lipoprotein (LDL) levels.

Disclosed are methods for managing a treatment in an adult individual having systemic lupus erythematosus (SLE) undergoing therapy for lupus nephritis. In aspects, the method comprises detecting a level of each of neutrophil gelatinase associated lipocalin (NGAL), kidney injury molecule 1 (KIM-1), monocyte chemotactic protein 1 (MCP-1), adiponectin, hemopexin, and ceruloplasmin in a urine sample obtained from the individual, the levels of which are used to determine a score at a first time point and a second time point. Whether the individual is responding to the therapy, in particular an induction phase of a therapy, is determined based on a comparison of the first and second score. The therapy may then be continued or adjusted based on that determination.

The present invention relates to a novel peptoid derivative, which is a partially modified adiponectin receptor peptide and has higher stability and superior p-AMPK activity than existing adiponectin receptor peptides, and has the advantage of being advantageous for drug formulation due to improved physical properties and activity. Therefore, the peptoid derivative of the present invention can be used for preventing or treating skin inflammatory diseases, wounds, hair loss, fibrosis, metabolic diseases, or cancer, and for preventing or improving aging, sensitive skin, wrinkles, or moisture.

This invention relates to the field of biodetection technology, disclosing a preservation solution, an adiponectin detection kit, its preparation method, and its application. The preservation solution comprises Tris, trehalose, Tween 20, sodium caseinate, PVP-10, Proclin-300, TX-100, surfactant S13, and glycine. This specific formulation effectively prevents quantum dot aggregation and maintains protein activity for a long time. The adiponectin detection kit is based on quantum dot immunofluorescence chromatography technology and includes components such as a sample pad, a release pad, and a nitrocellulose membrane. The release pad is simultaneously coated with quantum dot-labeled antibodies and unlabeled detection line antibodies, and the quantum dot-labeled antibodies are coupled in a cascade manner of "quantum dot-streptavidin-biotinylated antibody". This invention, through liquid dialysis linking technology and a unique release pad antibody premixing process, utilizes the signal amplification effect of the biotin system and the principle of homogeneous reaction, significantly improving the sensitivity, accuracy, and reagent stability of the detection.

The disclosure relates to a substance adiponectin and / or adiponectin receptor agonist (ARA) for use in the treatment of immune checkpoint blockade (ICB)-induced immune related adverse events (irAEs) in a subject, wherein the subject is preferably receiving checkpoint blockade therapy as a cancer therapy. As well as to a combination medication comprising adiponectin and / or adiponectin receptor agonist (ARA) and a photosensitizing agent for combined use in the treatment of immune checkpoint blockade (ICB)-induced immune related adverse events (irAEs) in a subject, wherein the treatment further comprises the extracorporeal irradiation of a blood sample of the subject with ultraviolet A (UVA), preferably extracorporeal photopheresis (ECP) therapy.

The invention belongs to the technical field of biomedical cosmetics, and discloses a double-target 5alpha-reductase and adiponectin receptor cyclic peptide as well as application and a preparation method thereof. The cyclic peptide is formed by cyclizing three amino acid units, namely arginine, phenylalanine and tyrosine through peptide bonds, and comprises pharmaceutically acceptable salts, solvates, stereoisomers or isotope labels of the cyclic peptide. The compound reduces generation of dihydrotestosterone by inhibiting 5alpha-reductase, activates an adiponectin receptor AdipoR pathway to promote energy metabolism and proliferation of hair papilla cells, and realizes double-target synergistic anti-alopecia. The invention also discloses application of the cyclopeptide in preparation of medicines or cosmetics for preventing or treating alopecia and a solid-phase synthesis preparation method. Through double-target synergistic interaction, the hair follicle cell proliferation rate can be remarkably increased at extremely low concentration, and the dosage is reduced compared with that of a traditional medicine; the composition is constructed by adopting physiological amino acid, has no systemic sex hormone side effect during local external use, and is high in safety.

The application discloses a preparation method of an electrochemical immunosensor for detecting adiponectin and a method for quantitatively detecting adiponectin by using the electrochemical immunosensor, proposes a new strategy for fixing adiponectin antibodies in one step, constructs an electrochemical immunosensor based on a gold sputtering silver screen-printed electrode (Au / AgSPE), and realizes rapid, high-sensitivity and stable detection of adiponectin, so as to promote the conversion of adiponectin detection technology to instant detection application. The detection process of the application only needs a portable electrochemical workstation, and does not need large biochemical analysis equipment. The screen-printed electrode and the sputtering process support large-scale production, and are favorable for reducing cost and popularization.

The objective is to provide a previously unknown adipocyte differentiation inducer. [Solution] A fat cell differentiation inducer containing sesamolinol as an active ingredient.

Provided are compositions comprising adiponectin or its mimics for treating tendon and ligament injuries, especially chronic tendinopathy; and methods for administering adiponectin or its mimics for treating or retarding the progression of tendinopathy as well as promoting surgical repair. Also provided is a biomaterial, such as a hydrogel, for minimal invasive delivery and sustained release of adiponectin or its mimics in tendons and ligaments.

This invention discloses an adiponectin enhancer, which contains phospholipid acetal as an active ingredient.

The invention discloses an application of a Cbf [beta] gene in preparation of a medicine for treating fracture nonunion, which is characterized in that the Cbf [beta] gene is overexpressed by targeting bone marrow adipocytes, so that the effects of maintaining the homeostasis of skeletal stem cells and promoting bone repair of Cbf [beta] protein in bone marrow adipocytes and adipogenic precursor cells (such as Adipoq + cells for short) are recovered or enhanced, and the bone fracture nonunion is improved. The bone marrow microenvironment is effectively improved, the steady state of skeletal stem cells is recovered, the function of the aged bone marrow fat cells can be directly improved, and then bone regeneration and fracture repair are promoted. The invention not only overcomes the defect of limited curative effect of the existing operation, transplantation and repair materials in the aged patients, but also has the advantages of high safety, strong targeting property, high efficiency and the like, and has obvious application value and wide clinical prospect in the treatment of aging fracture nonunion.

The invention relates to the technical field of monoclonal antibodies, in particular to an adiponectin ADP monoclonal antibody and application, the heavy chain sequence of the adiponectin ADP monoclonal antibody is shown as SEQ ID NO: 1, and the light chain sequence of the adiponectin ADP monoclonal antibody is shown as SEQ ID NO: 2. The adiponectin ADP monoclonal antibody disclosed by the invention has excellent specificity and sensitivity, can provide accurate and reliable reagent guarantee for related detection scenes, can be applied to a plurality of detection fields such as biochemical immunoturbidimetry, immunochromatography and ELISA (Enzyme-Linked Immunosorbent Assay), and realizes rapid, efficient and high-sensitivity clinical detection on an ADP antigen in serum.

The present invention pertains to the field of nutraceuticals, specifically to a synergistic nutraceutical composition designed to improve cardio-metabolic health. The composition, comprising berberine, anthocyanin(s), and astaxanthin, is intended to regulate aberrant metabolic biomarkers, including hyperglycemia, hypertriglyceridemia, elevated low-density lipoprotein (LDL) cholesterol, increased blood pressure, enhanced platelet aggregation, elevated serum transaminase activity and hypoadiponectinemia. This invention is particularly applicable to the therapeutic management of cardiometabolic pathologies, including Type 2 Diabetes Mellitus (T2DM), arterial hypertension, dyslipidemia, atherosclerosis, obesity, metabolic syndrome, non-alcoholic fatty liver disease (NAFLD), cerebrovascular accidents (stroke), and coronary artery disease, through the modulation of systemic metabolic homeostasis and by providing potential adjunctive efficacy alongside established pharmacotherapeutic regimens.